Information de reference pour ce titreAccession Number: | 01451458-200802012-00012.
|
Author: | Snydman, David R.
|
Institution: | Division of Geographic Medicine and Infectious Diseases and Department of Medicine, Tufts-New England Medical Center, and Tufts University School of Medicine, Boston, Massachusetts
|
Title: | |
Source: | Clinical Infectious Diseases. 46 (Supp. 2):S104-S111, February 1, 2008.
|
Abstract: | : Probiotics are generally defined as microorganisms that, when consumed, generally confer a health benefit on humans. There is considerable interest in probiotics for a variety of medical conditions, and millions of people around the world consume probiotics daily for perceived health benefits. Lactobacilli, bifidobacteria, and lactococci have generally been regarded as safe. There are 3 theoretical concerns regarding the safety of probiotics: (1) the occurrence of disease, such as bacteremia or endocarditis; (2) toxic or metabolic effects on the gastrointestinal tract; and (3) the transfer of antibiotic resistance in the gastrointestinal flora. In this review, the evidence for safety of the use of or the study of probiotics is examined. Although there are rare cases of bacteremia or fungemia related to the use of probiotics, epidemiologic evidence suggests no population increase in risk on the basis of usage data. There have been many controlled clinical trials on the use of probiotics that demonstrate safe use. The use of probiotics in clinical trials should be accompanied by the use of a data-safety monitoring board and by knowledge of the antimicrobial susceptibilities of the organism used.
(C) Copyright Oxford University Press 2008.
|
References: | 1. Saarela M, Mogensen G, Fonden R, Matto J, Mattila-Sandholm T. Probiotic bacteria: safety, functional and technological properties. J Biotechnol 2000; 84:197-215.
2. Salminen S, von Wright A, Morelli L, et al. Demonstration of safety of probiotics-a review. Int J Food Microbiol 1998; 44:93-106.
3. Senok AC, Ismaeel AY, Botta GA. Probiotics: facts and myths. Clin Microbiol Infect 2005; 11:958-66.
4. Soleman N, Laferl H, Kneifel W, et al. How safe is safe? A case of Lactobacillus paracasei ssp. paracasei endocarditis and discussion of the safety of lactic acid bacteria. Scand J Infect Dis 2003; 35:759-62.
5. Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 2005; 24:31-40.
6. De Groote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005; 24:278-80.
7. Kalima P, Masterton RG, Roddie PH, Thomas AE. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996; 32:165-7.
8. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004; 38:457-8.
9. Ledoux D, Labombardi VJ, Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int J STD AIDS 2006; 17:280-2.
10. Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. Guidelines for the evaluation of probiotics in food: report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food, London Ontario, Canada, April 30 and May 1, 2002, 2007. Available at: http://www.who.int/foodsafety/pu...- ouverture dans une nouvelle fenêtre. Accessed 26 November.
11. Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995; 21:224-6.
12. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 11:833-9.
13. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 2000; 30:54-60.
14. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999; 135:564-8.
15. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 2001; 357:1076-9.
16. Doron S, Snydman DR, Gorbach SL. Lactobacillus GG: bacteriology and clinical applications. Gastroenterol Clin North Am 2005; 34:483-98 ix.
17. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991; 88:90-7.
18. Kaila M, Isolauri E, Saxelin M, Arvilommi H, Vesikari T. Viable versus inactivated lactobacillus strain GG in acute rotavirus diarrhoea. Arch Dis Child 1995; 72:51-3.
19. Banaszkiewicz A, Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr 2005; 146:364-9.
20. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999; 104:e64.
21. Galpin L, Manary MJ, Fleming K, Ou CN, Ashorn P, Shulman RJ. Effect of Lactobacillus GG on intestinal integrity in Malawian children at risk of tropical enteropathy. Am J Clin Nutr 2005; 82:1040-5.
22. Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995; 20:333-8.
23. Manzoni P, Mostert M, Leonessa ML, et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis 2006; 42:1735-42.
24. Petschow BW, Figueroa R, Harris CL, Beck LB, Ziegler E, Goldin B. Effects of feeding an infant formula containing Lactobacillus GG on the colonization of the intestine: a dose-response study in healthy infants. J Clin Gastroenterol 2005; 39:786-90.
25. Srinivasan R, Meyer R, Padmanabhan R, Britto J. Clinical safety of Lactobacillus casei Shirota as a probiotic in critically ill children. J Pediatr Gastroenterol Nutr 2006; 42:171-3.
26. Shornikova AV, Casas IA, Isolauri E, Mykkanen H, Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997; 24:399-404.
27. Simakachorn N, Pichaipat V, Rithipornpaisarn P, Kongkaew C, Tongpradit P, Varavithya W. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J Pediatr Gastroenterol Nutr 2000; 30:68-72.
28. Shornikova AV, Casas IA, Mykkanen H, Salo E, Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997; 16:1103-7.
29. Clements ML, Levine MM, Black RE, et al. Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli. Antimicrob Agents Chemother 1981; 20:104-8.
30. Guarino A, Canani RB, Spagnuolo MI, Albano F, Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr 1997; 25:516-9.
31. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992; 116:353-7.
32. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17:895-904.
33. Rosenfeldt V, Michaelsen KF, Jakobsen M, et al. Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers. Pediatr Infect Dis J 2002; 21:417-9.
34. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-8.
35. Pirotta M, Gunn J, Chondros P, Grover S, Hurley S, Garland S. The PAV trial: does lactobacillus prevent post-antibiotic vulvovaginal candidiasis? Protocol of a randomised controlled trial [ISRCTN24141277]. BMC Fam Pract. 2004;5:5.
36. Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002; 74:123-7.
37. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation-a randomized, double-blind trial. Am J Transplant 2005; 5:125-30.
38. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39:1441-9.
39. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108-14.
40. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344:1046-9.
41. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90:439-48.
42. Williams AB, Yu C, Tashima K, Burgess J, Danvers K. Evaluation of two self-care treatments for prevention of vaginal candidiasis in women with HIV. J Assoc Nurses AIDS Care 2001; 12:51-7.
43. Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning B. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol 2001; 30:49-52.
44. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, Bruce AW. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003; 35:131-4.
45. Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) LA1 on Helicobacter pylori infection in humans. Digestion 1999; 60:203-9.
46. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome: a randomized double-blind placebo-controlled crossover study. Dig Liver Dis 2000; 32:294-301.
47. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13:1143-7.
48. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83:1256-64.
49. Henriksson A, Borody T, Clancy R. Probiotics under the regulatory microscope. Expert Opin Drug Saf 2005; 4:1135-43.
50. Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr 2001; 73(Suppl 2):465-70.
51. Reid G. Safety of lactobacillus strains as probiotic agents. Clin Infect Dis 2002; 35:349-50.
52. Clancy R. Immunobiotics and the probiotic evolution. FEMS Immunol Med Microbiol 2003; 38:9-12.
53. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol 2004; 12:412-6.
54. Kirjavainen PV, Tuomola EM, Crittenden RG, et al. In vitro adjesion and platelet aggregation properties of bacteremia-associated lactobacilli. Infect Immun 1999; 67:2653-5.
55. Yamazaki S, Machii K, Tsuyuki S, Momose H, Kawashima T, Ueda K. Immunological responses to monoassociated Bifidobacterium longum and their relation to prevention of bacterial invasion. Immunology 1985; 56:43-50.
56. McNaught CE, Woodcock NP, MacFie J, Mitchell CJ. A prospective randomised study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut 2002; 51:827-31.
57. Vesterlund S, Paltta J, Karp M, Ouwehand AC. Adhesion of bacteria to resected human colonic tissue: quantitative analysis of bacterial adhesion and viability. Res Microbiol 2005; 156:238-44.
58. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115:178-81.
59. Richard V, Van der Auwera P, Snoeck R, Daneau D, Meunier F. Nosocomial bacteremia caused by Bacillus species. Eur J Clin Microbiol Infect Dis 1988; 7:783-5.
60. Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.. J Clin Microbiol 1998; 36:325-6.
61. Spinosa MR, Wallet F, Courcol RJ, Oggioni MR. The trouble in tracing opportunistic pathogens: cholangitis due to Bacillus in a French hospital caused by a strain related to an Italian probiotic? Microb Ecol Health Dis 2000; 12:99-101.
62. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001; 135:484-92.
63. Salminen MK. Lactobacillus bacteremia, with special focus on the safety of probiotic Lactobacillus rhamnosus GG [doctoral dissertation]. Helsinki University of Helsinki, 2006.
64. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999; 28:1159-60.
65. Salminen MK, Tynkkynen S, Rautelin H, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 35:1155-60.
66. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38:62-9.
67. Sullivan A, Nord CE. Probiotic lactobacilli and bacteraemia in Stockholm. Scand J Infect Dis 2006; 38:327-31.
68. Lherm T, Monet C, Nougiere B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002; 28:797-801.
69. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii.. Am J Med 1998; 105:71-2.
70. Perapoch J, Planes AM, Querol A, et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. Eur J Clin Microbiol Infect Dis 2000; 19:468-70.
71. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000; 19:16-20.
72. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003; 41:5340-3.
73. Fredenucci I, Chomarat M, Boucaud C, Flandrois JP. Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy. Clin Infect Dis 1998; 27:222-3.
74. Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000; 8:504-5.
75. Marteau P, Pochart P, Flourie B, et al. Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of the colonic flora in humans. Am J Clin Nutr 1990; 52:685-8.
76. Midvedt T, Norman A. Bile acid transformation by microbial strains belonging to genera found in intestinal contents. Acta Pathol Microbiol Scand 1967; 7:629-38.
77. Lidbeck A, Nord CE, Gustafsson JA, Rafter J. Lactobacilli, anticarcinogenic activities and human intestinal microflora. Eur J Cancer Prev 1992; 1:341-53.
78. Gorbach SL, Goldin BR. The intestinal microflora and the colon cancer connection. Rev Infect Dis 1990; 12(Suppl 2):252-61.
79. Delia P, Sansotta G, Donato V, et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol 2002; 97:2150-2.
80. Goldin BR, Gualtieri LJ, Moore RP. The effect of Lactobacillus GG on the initiation and promotion of DMH-induced intestinal tumors in the rat. Nutr Cancer 1996; 25:197-204.
81. Connolly E, Abrahamsson T, Bjorksten B. Safety of D(-)-lactic acid producing bacteria in the human infant. J Pediatr Gastroenterol Nutr 2005; 41:489-92.
82. Bongaerts G, Bakkeren J, Severijnen R, et al. Lactobacilli and acidosis in children with short small bowel. J Pediatr Gastroenterol Nutr 2000; 30:288-93.
83. Ruseler-van Embden JG, van Lieshout LM, Gosselink MJ, Marteau P. Inability of Lactobacillus casei strain GG, L. acidophilus, and Bifidobacterium bifidum to degrade intestinal mucus glycoproteins. Scand J Gastroenterol 1995; 30:675-80.
84. Berg RD. Inhibition of Escherichia coli translocation from the gastrointestinal tract by normal cecal flora in gnotobiotic or antibiotic-decontaminated mice. Infect Immun 1980; 29:1073-81.
85. Yasui H, Shida K, Matsuzaki T, Yokokura T. Immunomodulatory function of lactic acid bacteria. Antonie Van Leeuwenhoek 1999; 76:383-9.
86. Mathur S, Singh R. Antibiotic resistance in food lactic acid bacteria-a review. Int J Food Microbiol 2005; 105:281-95.
87. Lin CF, Fung ZF, Wu CL, Chung TC. Molecular characterization of a plasmid-borne (pTC82) chloramphenicol resistance determinant (cat-TC) from Lactobacillus reuteri G4. Plasmid 1996; 36:116-24.
88. Gevers D, Danielsen M, Huys G, Swings J. Molecular characterization of tet(M) genes in Lactobacillus isolates from different types of fermented dry sausage. Appl Environ Microbiol 2003; 69:1270-5.
89. Luchansky JB, Miller L, et al. Molecular characterization of a plasmid-borne (pGT633) erythromycin resistance determinant (ermGT) from Lactobacillus reuteri 100-63. Plasmid 1994; 31:60-71.
90. Ahn C, Collins-Thompson D, Duncan C, Stiles ME. Mobilization and location of the genetic determinant of chloramphenicol resistance from Lactobacillus plantarum caTC2R. Plasmid 1992; 27:169-76.
91. Gasson MJ, Fitzgard GF. Gasson MJ, de Vos WM, eds. Gene transfer systems and transposition Genetics and biotechnology of lactic acid bacteria. London: Blackie Academics & Professional, 1997.
92. Steenson LR. High frequency intergeneric and intrageneric transfer conjugal transfer of drug resistance plasmids in Leuconostoc mesenteroides ssp. cremoris. J Dairy Sci 1991; 74:2912-9.
93. Morelli L, Sarra PG, Bottazzi V. In vivo transfer of pAM beta 1 from Lactobacillus reuteri to Enterococcus faecalis. J Appl Bacteriol 1988; 65:371-5.
94. Soedings B, Kleinschmidt J, Teuber M, Neve H. Assessment of abilities of conjugal transfer and stability of pAM[beta]1 in dairy lactobacilli with emphasis on thermophilic and non starter lactobacilli. Syst Appl Microbiol 1993; 16:296-302.
95. Klein G, Hallmann C, Casas IA, Abad J, Louwers J, Reuter G. Exclusion of vanA, vanB and vanC type glycopeptide resistance in strains of Lactobacillus reuteri and Lactobacillus rhamnosus used as probiotics by polymerase chain reaction and hybridization methods. J Appl Microbiol 2000; 89:815-24.
96. Tynkkynen S, Singh KV, Varmanen P. Vancomycin resistance factor of Lactobacillus rhamnosus GG in relation to enterococcal vancomycin resistance (van) genes. Int J Food Microbiol 1998; 41:195-204.
97. Tynkkynen S, Rautelin H, et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study. HIV Clin Trials 2004; 5:183-91.
98. Gorbach SL. Probiotics: their role in the treatment and prevention of disease. Expert Rev Anti Infect Ther 2006; 4:261-75.
99. Silva M, Jacobus NV, Deneke C, Gorbach SL. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987; 31:1231-3.
100. Hudault S, Lievin V, Bernet-Camard MF, Servin AL. Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C5 infection. Appl Environ Microbiol 1997; 63:513-8.
101. Salminen SJ, Donahue DC. Safety assessment of lactobacillus strain GG (ATCC 53103). Nutr Today 1996; 31(Suppl 6):12-15.
102. Isolauri E, Majamaa H, Arvola T, Rantala I, Virtanen E, Arvilommi H. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 1993; 105:1643-50.
103. Banasaz M, Norin E, Holma R, Midtvedt T. Increased enterocyte production in gnotobiotic rats mono-associated with Lactobacillus rhamnosus GG. Appl Environ Microbiol 2002; 68:3031-4.
104. Saxelin M. Lactobacillus GG-a human probiotic strain with thorough clinical documentation. Food Rev Int 1997; 13:293-313.
105. Chang TW, Gorbach SL. Effect of feeding Lactobacillus GG on lethal irradiation in mice. Diagn Microbiol Infect Dis 1987; 7:1-7.
106. Lahtinen SJ, Haskard CA, Ouwehand AC, Salminen SJ, Ahokas JT. Binding of aflatoxin B1 to cell wall components of Lactobacillus rhamnosus strain GG. Food Addit Contam 2004; 21:158-64.
107. Lim BK, Mahendran R, Lee YK, Bay BH. Chemopreventive effect of Lactobacillus rhamnosus on growth of a subcutaneously implanted bladder cancer cell line in the mouse. Jpn J Cancer Res 2002; 93:36-41.
108. Saxelin M, Salminen S. Phenotypic differences between commercial Lactobacillus rhamnosus GG and L. rhamnosus strains recovered from blood. Clin Infect Dis 2004; 39:1858-60.
109. Doron S, Gorbach SL. Probiotics: their role in the treatment and prevention of disease. Expert Rev Anti Infect Ther 2006; 4:261-75.
110. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis 2006; 42:e35-44.
111. Swenson JM, Facklam RR, Thornsberry C. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob Agents.Chemother 1990; 34:543-9.
|
Language: | English.
|
Document Type: | Supplement Articles.
|
Journal Subset: | Clinical Medicine. Life & Biomedical Sciences.
|
ISSN: | 1058-4838
|
DOI Number: | https://dx.doi.org/10.1086/52333...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|